Literature DB >> 15328161

Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock.

Jérôme Pugin1, Sabine Stern-Voeffray, Bruno Daubeuf, Michael A Matthay, Greg Elson, Irène Dunn-Siegrist.   

Abstract

In this paper, we show that plasma from patients with severe sepsis and septic shock but not normal plasma supports lipopolysaccharide (LPS) activation of epithelial cells expressing Toll-like receptor 4 (TLR4). Recombinant soluble myeloid differentiation protein-2 (MD-2) complemented normal plasma and allowed LPS activation of epithelial cells to levels measured with "septic" plasma, whereas soluble MD-2-depleted plasma lost its effects. The same "MD-2 activity" was found in urine from a patient with septic shock and in lung edema fluids from patients with adult respiratory distress syndrome (ARDS). Recombinant soluble MD-2 enabled LPS-dependent activation of epithelial cells bearing TLR4. LPS-binding protein (LBP) and soluble CD14 increased the sensitivity of TLR4-expressing epithelial cells to LPS but were not able to mediate LPS activation of these cells in the absence of soluble MD-2. An anti-MD-2 monoclonal antibody blocked LPS activation of TLR4-expressing cells only in the presence of septic plasma or septic urine. These results suggest that septic plasma containing soluble MD-2 leaking into the extravascular space supports LPS activation of TLR4-expressing epithelial cells. We therefore propose that soluble MD-2 is an important mediator of organ inflammation during sepsis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328161     DOI: 10.1182/blood-2003-04-1290

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Transcriptional profiling reveals a possible role for the timing of the inflammatory response in determining susceptibility to a viral infection.

Authors:  Thomas Ruby; Catherine Whittaker; David R Withers; Mounira K Chelbi-Alix; Veronique Morin; Anne Oudin; John R Young; Rima Zoorob
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  Innate immunity in the lungs.

Authors:  Thomas R Martin; Charles W Frevert
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Radioiodination of an endotoxin·MD-2 complex generates a novel sensitive, high-affinity ligand for TLR4.

Authors:  Athmane Teghanemt; Jerrold P Weiss; Theresa L Gioannini
Journal:  Innate Immun       Date:  2013-02-25       Impact factor: 2.680

4.  Toll-like receptor activation of human cells by synthetic triacylated lipid A-like molecules.

Authors:  Irène Dunn-Siegrist; Pierre Tissières; Geneviève Drifte; Jacques Bauer; Stéphane Moutel; Jérôme Pugin
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

Review 5.  Update on the role of Toll-like receptors during bacterial infections and sepsis.

Authors:  Sylvia Knapp
Journal:  Wien Med Wochenschr       Date:  2010-03

Review 6.  Alcoholic liver disease and the gut-liver axis.

Authors:  Gyongyi Szabo; Shashi Bala
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

7.  Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2.

Authors:  Wei Gu; You-an Shan; Jian Zhou; Dong-po Jiang; Lianyang Zhang; Ding-yuan Du; Zheng-guo Wang; Jian-xin Jiang
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

8.  Cooperation between PU.1 and CAAT/enhancer-binding protein beta is necessary to induce the expression of the MD-2 gene.

Authors:  Pierre Tissières; Tanguy Araud; Agnieszka Ochoda; Geneviève Drifte; Irène Dunn-Siegrist; Jérôme Pugin
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

Review 9.  Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells.

Authors:  Theresa L Gioannini; Jerrold P Weiss
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  Toll-like receptor 4 decoy, TOY, attenuates gram-negative bacterial sepsis.

Authors:  Keehoon Jung; Jung-Eun Lee; Hak-Zoo Kim; Ho Min Kim; Beom Seok Park; Seong-Ik Hwang; Jie-Oh Lee; Sun Chang Kim; Gou Young Koh
Journal:  PLoS One       Date:  2009-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.